Vancomycin is a glycopeptide antibiotic. Approved by FDA on January 29, 2018. Active against most strains of the microorganisms, both in vitro and in clinical infections. The mean elimination half-life of vancomycin from plasma is 4 to 6 hours in subjects with normal renal function. Vancomycin is approximately 55% serum protein-bound. It has a rapid onset of action. Effective against severe Gram +Ve Infection. Drug of choice for serious MRSA Infection. Susceptible to B- lactam & macrolide antibiotics.

Therapy Area: Antibiotic
Form: Injection
Packaging: 1X500mg Injection and 1x1gm Injection


Vancomycin 500mg/1000mg


Vancomycin exerts its bactericidal effect by inhibiting the polymerization of peptidoglycans in the bacterial cell wall. Vancomycin binds to d-alanyl d-alanine, which inhibits peptidoglycan synthase and the p-phospholipid carrier, thereby preventing the synthesis and polymerization of NAM and NAG within the peptidoglycan layer. Ultimately causes leakage of intracellular components, resulting in bacterial cell death.


  • Endocarditis
  • Peritonitis
  • Infection of Lungs and Skin
  • Septicemia caused by MRSA


This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About VANCOPRO

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.